2-((diethylamino)methyl)-N-(4-(trifluoromethyl)phenyl)-7-(3-(trifluoromethyl)pyridin-2-yl)quinazolin-4-amine | 573685-69-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-((diethylamino)methyl)-N-(4-(trifluoromethyl)phenyl)-7-(3-(trifluoromethyl)pyridin-2-yl)quinazolin-4-amine
• 英文别名: 2-(diethylaminomethyl)-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)pyridin-2-yl]quinazolin-4-amine
• CAS: 573685-69-5
• 化学式: C₂₆H₂₃F₆N₅
• 分子量: 519.493
• InChiKey: DSJMWSZZVBLHLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为产物：
  描述：

  [2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine 、 二乙胺 以 2,4-滴二甲胺盐 为溶剂， 生成 2-((diethylamino)methyl)-N-(4-(trifluoromethyl)phenyl)-7-(3-(trifluoromethyl)pyridin-2-yl)quinazolin-4-amine
  参考文献：
  名称：

  Aminoquinazolines as TRPV1 antagonists: Modulation of drug-like properties through the exploration of 2-position substitution

  摘要：

  A focused SAR exploration of the lead 4-aminoquinazoline TRPV1 antagonist 2 led to the discovery of compound 18. In rats, compound 18 is readily absorbed following oral dosing and demonstrates excellent in vivo potency and efficacy in an acute inflammatory pain model. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.036

文献信息

• Substituted quinazolin-4-ylamine analogues
  申请人：——

  公开号：US20040106616A1

  公开（公告）日：2004-06-03

  Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. 1

  提供了替代的喹唑啉-4-胺类似物。这些化合物是配体，可用于调节体内或体外特定受体的活性，并在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的此类配体的方法。
• Combination therapy for the treatment of pain
  申请人：Neurogen Corporation

  公开号：US20040142958A1

  公开（公告）日：2004-07-22

  Compositions and methods are provided for the treatment of pain. Compositions and methods are further provided for inhibiting the development of tolerance to addictive therapeutic agents (especially narcotic analgesics) in patients treated with such agents; for minimizing adverse effects (e.g., dependence) resulting from treatment with such addictive agents; and for enhancing pain relief resulting from narcotic analgesic administration. The compositions generally comprise a nontoxic VR1 antagonist, optionally in combination with an addictive therapeutic agent. Patients may be treated with a VR1 antagonist before, during or after administration of the addictive therapeutic agent to prevent, decrease the severity of, delay or treat tolerance and/or other adverse effects of the addictive agent in the patient.

  提供了用于治疗疼痛的组合物和方法。还提供了用于抑制接受此类药物（特别是麻醉镇痛剂）治疗的患者对成瘾性治疗剂量的耐受性发展，减少因使用此类成瘾性药物治疗而导致的不良反应（例如成瘾），以及增强因使用麻醉镇痛剂而产生的疼痛缓解的组合物和方法。这些组合物通常包括无毒的VR1拮抗剂，可选地与成瘾性治疗剂量结合使用。患者可以在接受成瘾性治疗剂量之前、期间或之后接受VR1拮抗剂治疗，以预防、减轻、延迟或治疗患者对成瘾性药物的耐受和/或其他不良反应。
• SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES
  申请人：Bakthavatchalam Rajagopal

  公开号：US20080015183A1

  公开（公告）日：2008-01-17

  Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了取代的喹唑啉-4-胺类似物。这些化合物是配体，可用于调节体内或体外特定受体活性，并在治疗与人类、家养伴侣动物和家畜动物的病理性受体激活相关的疾病方面特别有用。提供了用于治疗此类疾病的制药组合物和方法，以及用于受体定位研究的此类配体的使用方法。
• COMBINATION THERAPY FOR THE TREATMENT OF PAIN
  申请人：NEUROGEN CORPORATION

  公开号：EP1581225A1

  公开（公告）日：2005-10-05
• US7074799B2
  申请人：——

  公开号：US7074799B2

  公开（公告）日：2006-07-11